Umeclidinium with vilanterol inhalation
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Inhalation powder containing umeclidinium bromide and vilanterol (as trifenatate).
Drugs List
Therapeutic Indications
Uses
Chronic obstructive pulmonary disease
Dosage
Adults
One inhalation once daily, at the same time of the day to maintain bronchodilation.
Maximum dose is one inhalation.
Contraindications
Children under 18 years
Breastfeeding
Galactosaemia
Precautions and Warnings
Benign prostatic hyperplasia
Bladder outflow obstruction
Diabetes mellitus
Epileptic disorder
Glucose-galactose malabsorption syndrome
Hypokalaemia
Lactose intolerance
Narrow angle glaucoma
Pregnancy
Severe cardiovascular disorder
Severe hepatic impairment
Thyrotoxicosis
Urinary retention
Ensure patient has a fast acting bronchodilator available
Contains lactose
Check patient is using correct inhaler technique
Monitor blood glucose closely in patients with diabetes mellitus
Monitor serum K+ in patients on high dose steroids/xanthines/diuretics
May reduce serum potassium levels
Discontinue if paradoxical bronchospasm occurs
Advise patient not to use for relief of acute attacks
Advise patient to seek medical advice if treatment is ineffective
Use regularly to maintain freedom from symptoms
Pregnancy and Lactation
Pregnancy
Use umeclidinium with vilanterol with caution during pregnancy.
The manufacturer recommends that this medication should be used during pregnancy only if the expected benefit to the mother justifies the potential risk to the foetus.
There is no data from the use of umeclidinium with vilanterol. Studies in animals have shown reproductive toxicity at exposures which are not clinically relevant after administration of vilanterol.
Lactation
Umeclidinium with vilanterol is contraindicated during breastfeeding.
The manufacturer advises discontinuing breastfeeding or discontinuing umeclidinium with vilanterol treatment.
It is unknown whether umeclidinium or vilanterol are excreted in human milk. However, other beta2-adrenergic agonists are detected in human milk. A risk to the newborns/infants cannot be excluded.
Side Effects
Anaphylaxis
Angioedema
Atrial fibrillation
Bladder outflow obstruction
Blurred vision
Bronchospasm (paradoxical)
Constipation
Cough
Dizziness
Dry mouth
Dysgeusia
Dysphonia
Dysuria
Glaucoma
Headache
Hypersensitivity reactions
Hypokalaemia
Increased intra-ocular pressure
Nasopharyngitis
Oropharyngeal pain
Palpitations
Pharyngitis
Rash
Rhythm idioventricular
Sinusitis
Supraventricular tachycardia
Tachycardia
Tremor
Upper respiratory tract infection
Urinary retention
Urinary tract infections
Urticaria
Ventricular extrasystoles
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: January 2021
Reference Sources
Summary of Product Characteristics: Anoro Ellipta 55 micrograms/22 micrograms dry powder inhaler. GlaxoSmithKline UK. Revised September 2019.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 21 January 2021
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.